Clearmind Medicine Inc. (NasdaqCM: CMND)
Health Care · Pharmaceuticals · CA
$1.68
-3.45% today · -99.6% 1Y
Clearmind Medicine Inc. (NasdaqCM: CMND) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.58M and employs 4 people.
Over the last twelve months the share price has lost 99.6%, trading between 1.43 and 524.00.
Tweenvest scores Clearmind Medicine Inc. across four factors: quality 25/100. Its strongest factor is quality.
CMND price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.58M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -71.49
- Dividend yield
- —
- Beta (5Y)
- -1.18
- 52-week high
- $524.00
- 52-week low
- $1.43
- Avg volume (3M)
- —
- Shares outstanding
- 1.49M
- Employees
- 4
- Next earnings
- —
About Clearmind Medicine Inc.
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
- ISIN
- CA1850536006
- Founded
- 2017
- Listed since
- Nov 15, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,239.32 | -0.61% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.18 | +0.05% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.08 | +3.60% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.37 | +1.41% |
Figures last refreshed Aug 18, 2026.